An ongoing dialogue on HIV/AIDS, infectious diseases,
January 8th, 2012
Journal Club: In Early HIV Infection, Little Reason to Delay Therapy
Every experienced HIV clinician will recognize the following new-patient scenario:
- At least one, but often several negative HIV antibody tests in the past, generally due to being in a “high risk” group.
- Recent non-specific viral-type illness that, in hindsight, was undoubtedly acute HIV infection, undiagnosed.
- Now completely recovered, but found to be newly HIV antibody positive.
- Physical exam normal, CD4 500 or higher, HIV RNA in the moderate range (10-100K).
How should patients like these be managed? Specifically, should antiretroviral therapy be started, or should they be observed?
Over in Journal of Infectious Diseases, the so-called Setpoint study — a randomized strategy trial — investigated whether a 36-week period of treatment would delay the need to go on continuous HIV therapy, compared with observation. After 130 of a planned 150 patients were enrolled, a Data Safety Monitoring Board elected to stop the study due to this key finding: “… the higher rate of progression to needing treatment in the Deferred Treatment group (50%) versus the Immediate Treatment (10%) group.”
Importantly, the findings would have been even stronger in favor of Immediate Treatment if more up-to-date CD4 thresholds (500 rather than 350) were used as a criterion to start therapy. (The study was designed in the mid 2000s.)
How do these results influence practice? As I’ve noted before, patients diagnosed with recently-acquired HIV infection should be counseled that even if treatment is deferred, there is a high likelihood they will need to start treatment relatively soon.
It’s also time to retire the “you may have 10 years before needing to go on therapy” counseling, something we might have been prone to do in the past to soften the blow of someone hearing that they’re HIV positive. This kind of delay is highly unlikely, and may be limited to the small fraction of patients who have very low HIV RNA and very high CD4s.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- A Zoonotic Orthonairovirus from Febrile Patients in China September 3, 2026A new pathogenic orthonairovirus was identified in patients with a febrile illness in China. This virus was found in Haemaphysalis longicornis ticks in the same region.
- Pulmonary Nodules September 3, 2026This review summarizes the management of pulmonary nodules, with an emphasis on nodule type, imaging follow-up, cancer risk, and strategies to balance timely diagnosis with avoidance of unnecessary procedures.
- Fluid Resuscitation in Patients with Sepsis — For Whom the Balance Tolls September 3, 2026Improving the clinical treatment of patients with sepsis remains a major focus of critical care physicians worldwide.1,2 To date, few studies in either the pediatric or adult literature have established universal management principles that reliably improve outcomes, which attests to the heterogeneity of this syndrome. Fluid resuscitation is...
- Scrofuloderma September 3, 2026A 72-year-old man presented with a 2-month history of a painful lump on his neck. Cytologic analysis of fine-needle aspirate was consistent with suppurative lymphadenopathy. The lesion subsequently ulcerated and released purulent discharge.
- Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock September 3, 2026In children with septic shock, no significant difference was seen in the incidence of death, new renal-replacement therapy, or persistent kidney dysfunction with balanced fluid as compared with 0.9% saline for fluid resuscitation.
- A Zoonotic Orthonairovirus from Febrile Patients in China September 3, 2026